ProQR Therapeutics (PRQR) Insider Bart Filius Buys $231K of Stock

On June 26, 2026, Bart Filius purchased 150,000 shares of ProQR Therapeutics N.V. (NasdaqCM: PRQR) at an average price of $1.54 per share. This transaction, totaling $231,000, was not made under a pre-planned trading program.

Insider Buying and Selling at ProQR Therapeutics N.V.

Bart Filius's purchase was accompanied by other insider activity at ProQR Therapeutics. On June 2, Gylvin Lykke Hinsch also acquired shares, buying 14,595 and 14,495 shares in two separate transactions. Neither of these purchases was pre-planned, reinforcing the insiders' confidence in the company.

Other Institutional Activity in ProQR Therapeutics

In recent institutional activity, several funds adjusted their holdings in ProQR Therapeutics. Privium Fund Management B.V. grew its stake by 109,387 shares, bringing its total to 5,467,149 shares valued at approximately $8.86 million, marking a 2.0% increase. Aberdeen Group PLC increased its holdings by 366,289 shares, ending with 3,316,965 shares worth about $5.37 million, a 12.4% rise. On the other hand, Sio Capital Management, LLC reduced its position by 209,466 shares, now holding 1,954,715 shares valued at $3.17 million, reflecting a 9.7% decrease.

ProQR Therapeutics N.V. Stock Holds Steady

Shares of ProQR Therapeutics traded near $1.83 on Wednesday. The company, with a market cap of $161.2 million, has a forward P/E ratio of -2.25, indicating it is not profitable at the moment. Its beta of 0.061 suggests low volatility compared to the market. The stock's 52-week range is between $1.33 and $3.10, with a 50-day moving average of $1.60 and a 200-day moving average of $1.90. ProQR maintains a current ratio of 2.48 and a quick ratio of 2.39, with a debt-to-equity ratio of 41.85.

Analysts Set New Price Targets

Recently, analysts have maintained strong buy ratings for ProQR Therapeutics. On June 29, Evercore ISI Group maintained its buy rating with a $6.00 price target. Similarly, on June 26, Jones Trading reaffirmed its buy rating with a target of $10.00, and Chardan Capital maintained its buy rating with a $3.00 target. The consensus among analysts is a strong buy, with an average price target of $8.13.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a biotechnology company based in Leiden, Netherlands, focused on developing RNA-based therapies for genetic disorders. Using its Axiomer RNA editing technology, the company targets unmet medical needs. Its lead candidate, AX-0810, aims to treat cholestatic diseases, while other products target conditions like Rett syndrome and cardiovascular diseases. ProQR collaborates with Eli Lilly on potential therapies for liver and nervous system disorders.

Bottom Line

Bart Filius's recent purchase of ProQR shares indicates insider confidence in the company's future. ProQR Therapeutics is a clinical-stage biotech firm with promising RNA-based therapies in development. Investors often track such insider activities and analyst ratings to gauge potential future performance, though it's important to remember this information reflects past transactions and opinions.